Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Lisa A. Carey(UNC Lineberger Comprehensive Cancer Center), Haoquan Zhao(Baylor College of Medicine), Matthew V. Holt(Baylor College of Medicine), D.R. Mani(Broad Institute), Meenakshi Anurag(Baylor College of Medicine), Shyam M. Kavuri(Baylor College of Medicine), Viktoriya Korchina(Baylor College of Medicine), Steven A. Carr(Broad Institute), George Miles(Baylor College of Medicine), Donna M. Muzny(Baylor College of Medicine), Azra Krek(Icahn School of Medicine at Mount Sinai), HarshaVardhan Doddapaneni(Baylor College of Medicine), Jonathan T. Lei(Baylor College of Medicine), Matthew J. Ellis(Baylor College of Medicine), Richard A. Gibbs(Baylor College of Medicine), Yujia Wen(National Cancer Institute), Beom-Jun Kim(Baylor College of Medicine), LaTerrica Williams(Baylor College of Medicine), Terry Hyslop(Duke Cancer Institute), Charles M. Perou(Segeberger Kliniken), Linda McCart(Alliance for Clinical Trials in Oncology), Yongchao Dou(Baylor College of Medicine), Michael A. Gillette(Broad Institute), Aranzazu Fernandez-Martinez(University of North Carolina at Chapel Hill), Ana I. Robles(National Cancer Institute), Chang In Moon(Baylor College of Medicine), Francesca Petralia(Icahn School of Medicine at Mount Sinai), Tanmayi D. Vashist(Broad Institute), Eric J. Jaehnig(Baylor College of Medicine), Bing Zhang(Baylor College of Medicine), Shankha Satpathy(Broad Institute)
UNC Libraries
December 9, 2025
Cited by 0


Related Papers